# Shortness of Breath/Hypoxia â€“ RRT Protocol with Virtua Voorhees Addenda

**Primary Guideline:** European Society of Intensive Care Medicine (ESICM) Guidelines on Acute Respiratory Distress Syndrome 2023
**Official Source:** https://pmc.ncbi.nlm.nih.gov/articles/PMC10354163/
**Supporting Guidelines:**
- BTS/NICE/SIGN Joint Guideline on Asthma: Diagnosis, Monitoring and Chronic Management 2024
- Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Report
- American Thoracic Society/European Respiratory Society Clinical Practice Guidelines for Acute Respiratory Failure 2017 (Updated 2023)

## ENHANCED MERMAID FLOWCHART ALGORITHM

~~~mermaid
graph TD
    A["Respiratory Distress<br/>RR >20, SpO2 <95%"] --> B["ABC Assessment<br/>O2 Therapy + Monitoring"]
    
    B --> C["Initial Stabilization<br/>High-Flow O2, IV Access"]
    
    C --> D{"Immediate<br/>Life Threat?"}
    
    D -->|YES| E["Advanced Airway<br/>RSI Protocol"]
    D -->|NO| F["Focused Assessment<br/>History + Physical"]
    
    E --> G["Mechanical Ventilation<br/>Lung-Protective Strategy"]
    F --> H{"Primary<br/>Etiology?"}
    
    H -->|OBSTRUCTIVE| I["Bronchodilator Therapy<br/>Corticosteroids"]
    H -->|CARDIAC| J["Diuretics + Preload<br/>Reduction"]
    H -->|PARENCHYMAL| K["HFNO vs NIV<br/>Supportive Care"]
    H -->|MIXED| L["Treat Dominant<br/>Component First"]
    
    I --> M{"COPD vs<br/>Asthma?"}
    J --> N{"Flash Pulmonary<br/>Edema?"}
    K --> O{"Type of<br/>Respiratory Failure?"}
    L --> P["Combined Therapy<br/>Monitor Response"]
    
    M -->|COPD| Q["LABA/LAMA + Steroids<br/>Consider NIV"]
    M -->|ASTHMA| R["High-Dose Bronchodilators<br/>Systemic Steroids"]
    N -->|YES| S["BiPAP + Aggressive<br/>Diuresis"]
    N -->|NO| T["Standard HF Management<br/>ACE-I + Diuretics"]
    
    O -->|"TYPE I"| U["HFNO â‰¥30L/min<br/>Treat Underlying Cause"]
    O -->|"TYPE II"| V["NIV/BiPAP<br/>Ventilatory Support"]
    
    Q --> W{"Adequate<br/>Response?"}
    R --> W
    S --> W
    T --> W
    U --> W
    V --> W
    P --> W
    
    W -->|YES| X["Continue Treatment<br/>Wean Support"]
    W -->|NO| Y["Escalate Care<br/>Consider Intubation"]
    
    X --> Z["Disposition<br/>Based on Stability"]
    Y --> AA["RSI Protocol<br/>ICU Management"]
    G --> AA
    
    AA --> BB["Mechanical Ventilation<br/>ARDS Protocol if Indicated"]
    
    style A fill:#ffcccc
    style B fill:#ffe6cc
    style E fill:#ffaaaa
    style I fill:#fff2cc
    style J fill:#ccffcc
    style K fill:#e6ccff
    style AA fill:#ccffee
~~~

## STREAMLINED DYNAMIC CARD SYSTEM

### Card 0 â€“ Respiratory Distress Recognition & Initial Assessment (Node A â†’ B)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ« RESPIRATORY DISTRESS RRT ACTIVATION   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Recognition criteria:                â”‚
â”‚ â€¢ Respiratory rate >20/min             â”‚
â”‚ â€¢ SpO2 <95% on room air                â”‚
â”‚ â€¢ Accessory muscle use                 â”‚
â”‚ â€¢ Patient reporting dyspnea            â”‚
â”‚ â€¢ Altered mental status                â”‚
â”‚                                         â”‚
â”‚ ğŸš¨ ABC Assessment (Priority #1):        â”‚
â”‚ â€¢ Airway: Patent, protect if altered   â”‚
â”‚ â€¢ Breathing: Work of breathing, patternâ”‚
â”‚ â€¢ Circulation: Perfusion, vital signs  â”‚
â”‚ â€¢ Disability: Mental status changes    â”‚
â”‚                                         â”‚
â”‚ ğŸ’¨ Immediate oxygen therapy:            â”‚
â”‚ â€¢ Target SpO2: >92% (88-92% if COPD)   â”‚
â”‚ â€¢ Start with appropriate delivery methodâ”‚
â”‚ â€¢ Escalate based on response           â”‚
â”‚                                         â”‚
â”‚ [Next: Initial stabilization â–¶]        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 1 â€“ Initial Stabilization (Node C â†’ D)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸš€ INITIAL STABILIZATION PROTOCOL       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’¨ Oxygen delivery optimization:        â”‚
â”‚ â€¢ Nasal cannula: 1-6L/min              â”‚
â”‚ â€¢ Simple mask: 5-10L/min               â”‚
â”‚ â€¢ Non-rebreather: 15L/min              â”‚
â”‚ â€¢ High-flow nasal cannula: 30-60L/min  â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Monitoring establishment:            â”‚
â”‚ â€¢ Continuous pulse oximetry            â”‚
â”‚ â€¢ Cardiac monitoring                   â”‚
â”‚ â€¢ Blood pressure monitoring            â”‚
â”‚ â€¢ IV access Ã— 2                        â”‚
â”‚                                         â”‚
â”‚ ğŸ“‹ Essential orders:                    â”‚
â”‚ â€¢ Portable chest X-ray                â”‚
â”‚ â€¢ Arterial blood gas                   â”‚
â”‚ â€¢ BNP or NT-proBNP                     â”‚
â”‚ â€¢ Complete blood count                 â”‚
â”‚                                         â”‚
â”‚ [Next: Life threat assessment â–¶]       â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Recognition]              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2A â€“ Advanced Airway Management (Node E â†’ G)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸš¨ ADVANCED AIRWAY MANAGEMENT           â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ Immediate intubation indications:    â”‚
â”‚ â€¢ Impending respiratory failure        â”‚
â”‚ â€¢ Altered mental status (GCS â‰¤8)       â”‚
â”‚ â€¢ Hemodynamic instability              â”‚
â”‚ â€¢ Failed non-invasive ventilation      â”‚
â”‚                                         â”‚
â”‚ ğŸ”— RSI Protocol activation:             â”‚
â”‚ â€¢ [LINK TO RSI PROTOCOL]               â”‚
â”‚ â€¢ Pre-oxygenation optimization         â”‚
â”‚ â€¢ Rapid sequence intubation            â”‚
â”‚ â€¢ Post-intubation sedation             â”‚
â”‚                                         â”‚
â”‚ ğŸ« Lung-protective ventilation:         â”‚
â”‚ â€¢ Tidal volume: 6-8 mL/kg PBW          â”‚
â”‚ â€¢ Plateau pressure <30 cmH2O           â”‚
â”‚ â€¢ PEEP optimization                    â”‚
â”‚                                         â”‚
â”‚ [Next: Mechanical ventilation â–¶]       â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Life Threat Assessment]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2B â€“ Focused Assessment (Node F â†’ H)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ©º FOCUSED RESPIRATORY ASSESSMENT       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“ Essential history:                   â”‚
â”‚ â€¢ Onset: Acute vs chronic              â”‚
â”‚ â€¢ Triggers: Exertion, allergens        â”‚
â”‚ â€¢ Associated symptoms: Chest pain, feverâ”‚
â”‚ â€¢ Past medical history: Asthma, COPD, HFâ”‚
â”‚ â€¢ Medications: Recent changes           â”‚
â”‚                                         â”‚
â”‚ ğŸ” Focused physical exam:               â”‚
â”‚ â€¢ Vital signs with respiratory rate    â”‚
â”‚ â€¢ Chest inspection and auscultation    â”‚
â”‚ â€¢ Cardiac examination (S3, murmurs)    â”‚
â”‚ â€¢ Extremity examination (edema, cyanosis)â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Point-of-care assessments:           â”‚
â”‚ â€¢ Pulse oximetry trending              â”‚
â”‚ â€¢ Peak flow if able                    â”‚
â”‚ â€¢ POCUS lung/cardiac if available      â”‚
â”‚                                         â”‚
â”‚ [Next: Etiology determination â–¶]       â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Initial Stabilization]    â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3A â€“ Obstructive Disease Management (Node I â†’ M)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸŒªï¸ OBSTRUCTIVE AIRWAY DISEASE           â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š Bronchodilator therapy:              â”‚
â”‚ â€¢ Albuterol 2.5-5mg nebulizer q20min   â”‚
â”‚ â€¢ Ipratropium 0.5mg neb with albuterol â”‚
â”‚ â€¢ Consider continuous albuterol if severeâ”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Corticosteroid therapy:              â”‚
â”‚ â€¢ Methylprednisolone 125mg IV q6h       â”‚
â”‚ â€¢ Or prednisolone 40-80mg PO daily     â”‚
â”‚ â€¢ Duration: 5-7 days typically         â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Adjunctive therapies:                â”‚
â”‚ â€¢ Magnesium sulfate 2g IV over 20min   â”‚
â”‚ â€¢ Consider heliox if available         â”‚
â”‚ â€¢ Avoid sedatives in acute setting     â”‚
â”‚                                         â”‚
â”‚ [Next: COPD vs Asthma classification â–¶]â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Etiology Assessment]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3B â€“ Cardiac Etiology Management (Node J â†’ N)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’“ CARDIAC ETIOLOGY MANAGEMENT          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š Diuretic therapy:                    â”‚
â”‚ â€¢ Furosemide 40mg IV (or 2Ã— home dose) â”‚
â”‚ â€¢ May give 80-160mg IV for acute cases â”‚
â”‚ â€¢ Monitor electrolytes and renal functionâ”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Preload reduction:                   â”‚
â”‚ â€¢ Nitroglycerin 0.4mg SL q5min Ã— 3     â”‚
â”‚ â€¢ Or nitroglycerin 10-20 mcg/min IV    â”‚
â”‚ â€¢ Avoid if hypotensive                 â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Diagnostic workup:                   â”‚
â”‚ â€¢ BNP/NT-proBNP levels                 â”‚
â”‚ â€¢ Echocardiogram if available          â”‚
â”‚ â€¢ 12-lead ECG for ischemia             â”‚
â”‚                                         â”‚
â”‚ [Next: Flash pulmonary edema check â–¶]  â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Etiology Assessment]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3C â€“ Parenchymal Disease Management (Node K â†’ O)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ« PARENCHYMAL LUNG DISEASE             â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸŒŠ High-flow nasal cannula (2023 update):â”‚
â”‚ â€¢ Flow rate: â‰¥30 L/min minimum          â”‚
â”‚ â€¢ FiO2: Start 60-80%, titrate to targetâ”‚
â”‚ â€¢ Temperature: 37Â°C for comfort        â”‚
â”‚ â€¢ Preferred over standard O2 therapy   â”‚
â”‚                                         â”‚
â”‚ ğŸ˜· Non-invasive ventilation option:     â”‚
â”‚ â€¢ Consider if HFNO inadequate          â”‚
â”‚ â€¢ BIPAP: IPAP 10-15, EPAP 5-8 cmH2O    â”‚
â”‚ â€¢ Monitor for intolerance              â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Supportive care:                     â”‚
â”‚ â€¢ Antibiotics if infection suspected   â”‚
â”‚ â€¢ Corticosteroids for specific conditionsâ”‚
â”‚ â€¢ Avoid excessive fluid administration â”‚
â”‚                                         â”‚
â”‚ [Next: Respiratory failure type â–¶]     â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Etiology Assessment]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4A â€“ COPD Management (Node Q â†’ W)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ« COPD EXACERBATION (GOLD 2023)        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š Updated bronchodilator protocol:     â”‚
â”‚ â€¢ LABA/LAMA combination preferred      â”‚
â”‚ â€¢ Albuterol/ipratropium 2.5/0.5mg neb â”‚
â”‚ â€¢ May use continuous nebulizers        â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Corticosteroid therapy (2023 update):â”‚
â”‚ â€¢ Prednisolone 40mg daily Ã— 5 days     â”‚
â”‚ â€¢ Avoid longer courses                 â”‚
â”‚ â€¢ Consider blood eosinophils >300/Î¼L   â”‚
â”‚                                         â”‚
â”‚ ğŸ˜· NIV consideration (Type II RF):       â”‚
â”‚ â€¢ pH 7.25-7.35 with hypercapnia       â”‚
â”‚ â€¢ BIPAP: IPAP 15-25, EPAP 4-8 cmH2O    â”‚
â”‚ â€¢ Reduces intubation risk significantlyâ”‚
â”‚                                         â”‚
â”‚ [Next: Response assessment â–¶]          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Obstructive Classification]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4B â€“ Asthma Management (Node R â†’ W)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸŒ¬ï¸ ACUTE ASTHMA (BTS/NICE/SIGN 2024)   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š High-dose bronchodilator therapy:    â”‚
â”‚ â€¢ Albuterol 2.5-5mg neb q20min Ã— 3     â”‚
â”‚ â€¢ Add ipratropium 0.5mg to first 3 dosesâ”‚
â”‚ â€¢ Consider continuous albuterol if severeâ”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Systemic corticosteroids:            â”‚
â”‚ â€¢ Prednisolone 40-50mg PO daily        â”‚
â”‚ â€¢ Or hydrocortisone 200mg IV q6h       â”‚
â”‚ â€¢ Start early in treatment             â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Adjunctive therapies:                â”‚
â”‚ â€¢ Magnesium sulfate 2g IV over 20min   â”‚
â”‚ â€¢ Only for severe/life-threatening casesâ”‚
â”‚ â€¢ Avoid unnecessary IV fluids          â”‚
â”‚                                         â”‚
â”‚ [Next: Response assessment â–¶]          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Obstructive Classification]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 5A â€“ Flash Pulmonary Edema (Node S â†’ W)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸŒŠ FLASH PULMONARY EDEMA MANAGEMENT     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ˜· BiPAP/CPAP (immediate):              â”‚
â”‚ â€¢ CPAP 10-15 cmH2O or BiPAP            â”‚
â”‚ â€¢ Reduces preload and afterload        â”‚
â”‚ â€¢ Improves oxygenation rapidly         â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Aggressive diuresis:                 â”‚
â”‚ â€¢ Furosemide 80-160mg IV bolus         â”‚
â”‚ â€¢ May repeat or use continuous infusionâ”‚
â”‚ â€¢ Monitor for hypovolemia              â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Additional preload reduction:        â”‚
â”‚ â€¢ Nitroglycerin SL then IV infusion    â”‚
â”‚ â€¢ Consider morphine 2-4mg IV (cautiously)â”‚
â”‚ â€¢ Avoid ACE inhibitors acutely         â”‚
â”‚                                         â”‚
â”‚ [Next: Response assessment â–¶]          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Flash Edema Assessment]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 5B â€“ Type I Respiratory Failure (Node U â†’ W)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”´ TYPE I RESPIRATORY FAILURE (HYPOXEMIC)â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸŒŠ HFNC optimization (2023 guidelines):  â”‚
â”‚ â€¢ Flow rate: 30-60 L/min               â”‚
â”‚ â€¢ FiO2: Titrate to SpO2 target         â”‚
â”‚ â€¢ Preferred over conventional oxygen   â”‚
â”‚ â€¢ Monitor for clinical improvement     â”‚
â”‚                                         â”‚
â”‚ ğŸ¯ Treat underlying causes:             â”‚
â”‚ â€¢ Pneumonia: Antibiotics              â”‚
â”‚ â€¢ PE: Anticoagulation                 â”‚
â”‚ â€¢ ARDS: Lung-protective strategies     â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Monitoring parameters:               â”‚
â”‚ â€¢ SpO2 target >92% (88-92% if COPD)    â”‚
â”‚ â€¢ Work of breathing assessment         â”‚
â”‚ â€¢ Mental status changes                â”‚
â”‚                                         â”‚
â”‚ [Next: Response assessment â–¶]          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: RF Type Classification]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 5C â€“ Type II Respiratory Failure (Node V â†’ W)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”µ TYPE II RESPIRATORY FAILURE (HYPERCAPNIC)â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ˜· NIV/BiPAP (2023 recommendations):    â”‚
â”‚ â€¢ IPAP: 15-25 cmH2O                    â”‚
â”‚ â€¢ EPAP: 4-8 cmH2O                      â”‚
â”‚ â€¢ Backup rate: 12-15/min               â”‚
â”‚ â€¢ FiO2: Titrate to target              â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Success indicators:                  â”‚
â”‚ â€¢ pH improvement >7.30                 â”‚
â”‚ â€¢ PaCO2 reduction                      â”‚
â”‚ â€¢ Reduced work of breathing            â”‚
â”‚                                         â”‚
â”‚ âš ï¸ Failure indicators:                  â”‚
â”‚ â€¢ Worsening pH <7.25                   â”‚
â”‚ â€¢ Patient intolerance                  â”‚
â”‚ â€¢ Hemodynamic instability              â”‚
â”‚                                         â”‚
â”‚ [Next: Response assessment â–¶]          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: RF Type Classification]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 6 â€“ Treatment Response Assessment (Node W)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“Š TREATMENT RESPONSE EVALUATION        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ âœ… Positive response indicators:         â”‚
â”‚ â€¢ Improved SpO2 to target range        â”‚
â”‚ â€¢ Reduced respiratory rate             â”‚
â”‚ â€¢ Decreased work of breathing          â”‚
â”‚ â€¢ Improved mental status               â”‚
â”‚ â€¢ Stable or improved vital signs       â”‚
â”‚                                         â”‚
â”‚ âš ï¸ Treatment failure indicators:         â”‚
â”‚ â€¢ Persistent hypoxemia                 â”‚
â”‚ â€¢ Worsening hypercapnia                â”‚
â”‚ â€¢ Increased work of breathing          â”‚
â”‚ â€¢ Hemodynamic deterioration            â”‚
â”‚                                         â”‚
â”‚ â“ Adequate response to treatment?      â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ YES â†’ Continue current therapy      â”‚
â”‚ ğŸ”˜ NO â†’ Escalate to advanced support   â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 7A â€“ Continued Treatment (Node X â†’ Z)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ âœ… SUCCESSFUL TREATMENT CONTINUATION     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“ˆ Treatment optimization:              â”‚
â”‚ â€¢ Continue effective therapies         â”‚
â”‚ â€¢ Wean oxygen as tolerated             â”‚
â”‚ â€¢ Reduce respiratory support gradually â”‚
â”‚ â€¢ Monitor for rebound symptoms         â”‚
â”‚                                         â”‚
â”‚ ğŸ”„ Ongoing assessment:                  â”‚
â”‚ â€¢ Vital signs q15-30min initially      â”‚
â”‚ â€¢ Pulse oximetry continuous            â”‚
â”‚ â€¢ Repeat ABG if indicated              â”‚
â”‚ â€¢ Chest X-ray follow-up                â”‚
â”‚                                         â”‚
â”‚ ğŸ“‹ Discharge planning preparation:      â”‚
â”‚ â€¢ Medication reconciliation            â”‚
â”‚ â€¢ Follow-up appointments               â”‚
â”‚ â€¢ Patient education                    â”‚
â”‚                                         â”‚
â”‚ [Next: Disposition planning â–¶]         â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Response Assessment]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 7B â€“ Escalation of Care (Node Y â†’ AA)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ â¬†ï¸ ESCALATION TO ADVANCED SUPPORT       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸš¨ Failed non-invasive management:      â”‚
â”‚ â€¢ Worsening respiratory status         â”‚
â”‚ â€¢ Unable to maintain oxygenation       â”‚
â”‚ â€¢ Patient exhaustion                   â”‚
â”‚ â€¢ Hemodynamic instability              â”‚
â”‚                                         â”‚
â”‚ ğŸ”— RSI Protocol preparation:            â”‚
â”‚ â€¢ [LINK TO RSI & ADVANCED AIRWAY]      â”‚
â”‚ â€¢ Pre-oxygenation optimization         â”‚
â”‚ â€¢ Medications prepared                 â”‚
â”‚ â€¢ Airway equipment ready               â”‚
â”‚                                         â”‚
â”‚ ğŸ¥ ICU coordination:                    â”‚
â”‚ â€¢ Notify ICU team                      â”‚
â”‚ â€¢ Prepare for transfer                 â”‚
â”‚ â€¢ Continue support during preparation  â”‚
â”‚                                         â”‚
â”‚ [Next: Mechanical ventilation â–¶]       â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Response Assessment]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 8A â€“ Mechanical Ventilation (Node BB - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ« MECHANICAL VENTILATION & ICU CARE    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ›¡ï¸ Lung-protective ventilation:         â”‚
â”‚ â€¢ Tidal volume: 6-8 mL/kg PBW          â”‚
â”‚ â€¢ Plateau pressure: <30 cmH2O          â”‚
â”‚ â€¢ PEEP optimization based on FiO2      â”‚
â”‚ â€¢ Driving pressure: <15 cmH2O          â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š ARDS protocol if indicated:          â”‚
â”‚ â€¢ Berlin criteria assessment           â”‚
â”‚ â€¢ Prone positioning for severe cases   â”‚
â”‚ â€¢ Conservative fluid strategy          â”‚
â”‚ â€¢ Consider ECMO if refractory          â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Sedation and paralysis:              â”‚
â”‚ â€¢ Adequate sedation for comfort        â”‚
â”‚ â€¢ Minimize deep sedation               â”‚
â”‚ â€¢ Neuromuscular blockade if needed     â”‚
â”‚                                         â”‚
â”‚ ğŸ¯ Weaning strategy:                    â”‚
â”‚ â€¢ Daily spontaneous breathing trials   â”‚
â”‚ â€¢ Minimize ventilator days             â”‚
â”‚ â€¢ Early mobility when appropriate      â”‚
â”‚                                         â”‚
â”‚ âœ… MECHANICAL VENTILATION ACTIVE       â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Advanced Support]         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 8B â€“ Disposition Planning (Node Z - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¥ DISPOSITION & FOLLOW-UP PLANNING     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“ Disposition options:                 â”‚
â”‚                                         â”‚
â”‚ ğŸ”´ ICU admission:                       â”‚
â”‚ â€¢ Mechanical ventilation required      â”‚
â”‚ â€¢ Hemodynamic instability             â”‚
â”‚ â€¢ Multiple organ dysfunction           â”‚
â”‚                                         â”‚
â”‚ ğŸŸ¡ Telemetry/Step-down:                 â”‚
â”‚ â€¢ NIV/BiPAP requirements               â”‚
â”‚ â€¢ High oxygen needs                    â”‚
â”‚ â€¢ Frequent monitoring needed           â”‚
â”‚                                         â”‚
â”‚ ğŸŸ¢ Medical floor:                       â”‚
â”‚ â€¢ Stable on supplemental oxygen        â”‚
â”‚ â€¢ Controlled symptoms                  â”‚
â”‚ â€¢ Low risk for deterioration           â”‚
â”‚                                         â”‚
â”‚ ğŸ  Discharge considerations:             â”‚
â”‚ â€¢ Room air or low-flow oxygen          â”‚
â”‚ â€¢ Stable vital signs                   â”‚
â”‚ â€¢ Adequate social support              â”‚
â”‚                                         â”‚
â”‚ ğŸ“‹ Follow-up coordination:              â”‚
â”‚ â€¢ Pulmonology: 1-2 weeks if indicated  â”‚
â”‚ â€¢ Primary care: Within 1 week          â”‚
â”‚ â€¢ Cardiology if cardiac etiology       â”‚
â”‚                                         â”‚
â”‚ âœ… DISPOSITION PROTOCOL COMPLETE       â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Continued Treatment]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

## VIRTUA VOORHEES RESPIRATORY DISTRESS ADDENDA

### **Enhanced RRT Response Program:**
- **Respiratory Therapy Integration:** 24/7 coverage with HFNC and NIV expertise
- **Advanced Equipment:** High-flow nasal cannula units on all floors
- **RSI Protocol Integration:** Seamless transition for failed non-invasive ventilation
- **Quality Metrics:** HFNC success rates, NIV failure rates, intubation avoidance

### **Updated 2023-2024 Guidelines Integration:**
**ESICM ARDS Guidelines 2023:**
- **HFNC preferred:** â‰¥30 L/min flow rate as first-line for acute respiratory failure[1][2]
- **NIV recommendations:** Conditional recommendation for select ARF conditions
- **Prone positioning:** Early implementation for moderate-severe ARDS
- **Conservative fluid strategy:** Recommended unless hemodynamic instability

**BTS/NICE/SIGN Asthma Guidelines 2024:**
- **Combination therapy:** ICS/formoterol preferred over SABA alone[51]
- **MART strategy:** Maintenance and reliever therapy for persistent symptoms
- **Early corticosteroids:** Systemic steroids within first hour of severe exacerbation
- **Magnesium sulfate:** Reserved for severe/life-threatening cases only

### **Advanced Respiratory Support:**
**High-Flow Nasal Cannula (Updated 2023):**
- **Flow rates:** 30-60 L/min (minimum 30 L/min per ESICM guidelines)
- **FiO2 delivery:** More precise than conventional oxygen therapy
- **Patient comfort:** Heated and humidified gas delivery
- **Efficacy:** Reduces work of breathing and improves oxygenation

**Non-Invasive Ventilation Optimization:**
- **BiPAP settings:** IPAP 15-25 cmH2O, EPAP 4-8 cmH2O for COPD
- **Success predictors:** pH >7.25, able to protect airway, cooperative patient
- **Failure criteria:** pH <7.25, hemodynamic instability, decreased consciousness

### **GOLD 2023 COPD Updates:**
**New Classification System:**
- **Group A:** Low symptoms, low exacerbation risk
- **Group B:** High symptoms, low exacerbation risk  
- **Group E:** High exacerbation risk (combines former C&D)[7][25]

**Treatment Modifications:**
- **LABA/LAMA preferred:** Initial therapy for Groups B and E
- **Eosinophil-guided:** ICS use when blood eosinophils â‰¥300/Î¼L
- **Triple therapy:** LABA/LAMA/ICS for Group E with high eosinophils

### **Point-of-Care Ultrasound Integration:**
**Lung Ultrasound Applications:**
- **B-lines:** Pulmonary edema assessment
- **Consolidation:** Pneumonia diagnosis
- **Pleural effusion:** Identification and quantification
- **Pneumothorax:** Bedside diagnosis

**Cardiac Ultrasound:**
- **LV function:** Systolic function assessment
- **Right heart:** RV strain from PE or pulmonary hypertension
- **IVC assessment:** Volume status determination

### **Oxygen Delivery Hierarchy (2023 Evidence-Based):**
1. **Room air:** SpO2 >95% goal
2. **Nasal cannula:** 1-6 L/min
3. **Simple mask:** 5-10 L/min  
4. **Non-rebreather:** 15 L/min
5. **High-flow nasal cannula:** 30-60 L/min (preferred over conventional)
6. **Non-invasive ventilation:** BiPAP/CPAP
7. **Mechanical ventilation:** Lung-protective strategy

### **Quality Improvement Metrics:**
- **Recognition time:** Goal <5 minutes from RRT activation
- **HFNC initiation:** Goal <30 minutes for appropriate candidates
- **NIV success rate:** Target >80% for appropriate COPD exacerbations
- **Intubation avoidance:** Track successful non-invasive management

### **Medication Safety Updates:**
**Bronchodilator Optimization:**
- **Albuterol dosing:** 2.5-5mg nebulized, may repeat q20min Ã— 3
- **Ipratropium addition:** 0.5mg with albuterol for first 3 doses
- **Continuous nebulizers:** For severe/life-threatening cases only

**Corticosteroid Protocols:**
- **Asthma:** Prednisolone 40-50mg daily Ã— 5-7 days
- **COPD:** Prednisolone 40mg daily Ã— 5 days (avoid longer courses)
- **IV option:** Hydrocortisone 200mg q6h or methylprednisolone 125mg q6h

### **Integration with Other Protocols:**
- **RSI Protocol:** Direct link for failed non-invasive ventilation
- **Shock Protocol:** For hemodynamically unstable patients
- **Code Blue:** For respiratory arrest scenarios
- **AKI Protocol:** For patients requiring aggressive diuresis

### **Special Population Considerations:**
**COPD Patients:**
- **Target SpO2:** 88-92% to avoid CO2 retention
- **NIV threshold:** pH 7.25-7.35 with hypercapnia
- **Steroid duration:** Limited to 5 days to minimize side effects

**Heart Failure Patients:**
- **Fluid restriction:** Careful monitoring of input/output
- **BiPAP benefits:** Reduces preload and afterload
- **Diuretic monitoring:** Watch for electrolyte imbalances

**Immunocompromised Patients:**
- **Early intervention:** Lower threshold for advanced support
- **Infection screening:** Comprehensive workup for opportunistic pathogens
- **Steroid caution:** Balance benefits vs immunosuppression risks

## REFERENCE GUIDELINES
- **2023 ESICM Guidelines on Acute Respiratory Distress Syndrome**
- **2024 BTS/NICE/SIGN Joint Guideline on Asthma: Diagnosis, Monitoring and Chronic Management**
- **2023 GOLD Report: Global Strategy for Diagnosis, Management and Prevention of COPD**
- **2017 ATS/ERS Clinical Practice Guidelines: Noninvasive Ventilation for Acute Respiratory Failure (Updated 2023)**
- **Virtua Health System Respiratory Distress Protocol v2025**

**This comprehensive protocol integrates the latest evidence-based respiratory failure management with advanced non-invasive support modalities, optimized for rapid recognition, appropriate escalation, and excellent patient outcomes at Virtua Voorhees.**
